The latest price target for Fennec Pharmaceuticals (NASDAQ:FENC) was reported by HC Wainwright & Co. on August 21, 2025. The analyst firm set a price target for $13.00 expecting FENC to rise to within ...

The average one-year price target for Fennec Pharmaceuticals (TSX:FRX) has been revised to $21.57 / share. This is an increase of 10.41% from the prior estimate of $19.53 dated November 16, 2025. The ...

$364.74M Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Fennec Pharmaceuticals (FENC – Research Report), with a price target of $15.00. The company’s shares opened ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Fennec Pharmaceuticals (FENC – Research Report) and BioLife Solutions (BLFS – Research Report) with ...

Investing.com - H.C. Wainwright raised its price target on Fennec Pharmaceuticals Inc. (NASDAQ:FENC) to $16 from $13 while maintaining a Buy rating, according to a note released Thursday. The firm ...